Wyeth-Ayerst Crinone comparative claims in press release are misleading -- FDA ad division.
Executive Summary
WYETH-AYERST CRINONE PRESS RELEASE DISSEMINATION DESPITE DDMAC WARNING draws May 19 letter from FDA's Division of Drug Marketing, Advertising & Communications to Wyeth-Ayerst Associate Director of Regulatory Affairs Joan Barton. DDMAC Regulatory Review Officer Lisa Stockbridge, PhD, reminded Barton: "I told you that I had concerns about at least one presentation before I had finished the first read of the press release."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth